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Background. Highly pathogenic avian inﬂuenza H5N1 viruses remain a threat to human health, with potential
to become pandemic agents.
Methods. This phase III, placebo-controlled, observer-blinded study evaluated the immunogenicity, cross-
reactivity, safety, and lot consistency of 2 doses of oil-in-water (AS03A) adjuvanted H5N1 A/Indonesia/05/2005
(3.75 lg hemagglutinin antigen) prepandemic candidate vaccine in 4561 adults aged 18–91 years.
Results. Humoral antibody responses in the H5N1 vaccine groups fulﬁlled US and European immunogenicity
licensurecriteriaforpandemicvaccinesinallagestrata21daysaftertheseconddose.At6monthsafter the administration
of the primary dose, serum antibody seroconversion rates continued to fulﬁll licensure criteria. Neutralizing cross-clade
immune responses were demonstrated against clade 1 A/Vietnam/1194/2004. Consistency was demonstrated for 3
consecutive H5N1 vaccine lots. Temporary injection-site pain was more frequent with H5N1 vaccine than placebo
(89.3% and 70.7% in the 18–64 and R65 years strata vs 22.2% and 14.4% in the placebo groups). Unsolicited adverse
event frequency, including medically attended and serious events, was similar between groups through day 364.
Conclusions. In adults and elderly adults, AS03A-adjuvanted H5N1 candidate vaccine was highly immunogenic
for A/Indonesia/05/2005, with cross-reactivity against A/Vietnam/1194/2004. Temporary injection site reactions
were more frequent with H5N1 vaccine than placebo, although the H5N1 vaccine was well tolerated overall.
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remain a threat. Antigenic and phylogenetic analyses of
A(H5N1) viruses reported by the World Health Organization
in February 2009 indicated that multiple clade 2 subclades were
responsible for the majority of human cases since the re-
emergence of avian-origin inﬂuenza in 2003 [1].
Adjuvanted inactivated split-virion inﬂuenza vac-
cines containing the avian-origin H5N1 hemagglutinin antigen
(HA) have been shown to be highly immunogenic and well
tolerated in children and adults [2–5]. Reduction in the amount
of antigen needed per dose, which is paramount to meet de-
mand for vaccine during a pandemic, was achieved by formu-
lation with an Adjuvant System (AS03) containing a-tocopherol
and squalene in an oil-in-water emulsion [4]. The AS03 Adju-
vant System enhances the immune response by triggering the
transient production of cytokines at the injection site and in the
lymph nodes and by promoting antigen presentation by
mononuclear phagocytes [6]. While experience during the
swine-origin H1N1 pandemic demonstrated that a single 3.75
lg HA dose of AS03A-adjuvanted vaccine was sufﬁciently im-
munogenic in adults and children, data concerning AS03A-
adjuvanted avian-origin H5N1 vaccines have repeatedly
shownthattwo 3.75 lg doses of HA(A/Vietnam/119/2004or A/
Indonesia/05/2005) were needed to fulﬁll immunogenicity
licensure criteria [3, 4]. In this phase III, randomized,
placebo-controlled, observer-blinded study, we assessed the
immunogenicity, safety, and lot-to-lot consistency of an AS03A-
adjuvanted A/Indonesia/05/2005 (clade 2.1) inﬂuenza vaccine
in adults aged 18–64 years and in adults aged R65 years.
METHODS
Design
This was a multicenter, randomized, placebo-controlled,
observer-blinded study conducted in North America. The
objective was to assess the immunogenicity and safety of 2
doses of an AS03A-adjuvanted H5N1 A/Indonesia/05/2005
inﬂuenza vaccine in adults aged R18 years. The equivalence
of immunogenicity between 3 different lots of antigen
combined with 3 lots of adjuvant was also examined.
Eligible participants were healthy or had controlled chronic
illness. Women of child-bearing age were not pregnant and
agreed to use reliable methods of contraception. All partic-
ipants provided informed written consent. The protocol was
approved by research ethics boards or local or central insti-
tutional review boards and was conducted in accordance with
Good Clinical Practice, the Declaration of Helsinki, the US
Code of Federal Regulations for the Protection of Human
Subjects, the Canadian TriCouncil Policy Statement on Ethical
Conduct for Research Involving Humans, and all relevant
Canadian and US regulations.
Vaccines and Schedule
GlaxoSmithKline (GSK) Biologicals manufactured the H5N1
vaccine antigen in Ste-Foy, Quebec, Canada. Each dose con-
tained 3.75 lg HA of A/Indonesia/05/2005 (IBCDC-RG2;
Centers for Disease Control and Prevention). The adjuvant
(AS03A) was a 10% (by volume) DL-a-tocopherol–based oil-
in-water emulsion. The placebo control was phosphate-buffered
saline.
A randomization list was generated by GSK Biologicals using
a blocking scheme. Participants were randomized 3:1 to receive
vaccine or placebo, and vaccine recipients were further ran-
domized 1:1:1 to receive 1 of 3 lots. A minimization algorithm
was used to balance the randomization by site and age strata
(18–30, 31–49, 50–64, 65–74, and R75 years).
Participants received 1 dose of vaccine or placebo intramus-
cularly on day 0 (deltoid, nondominant arm) and a second dose
on day 21 (deltoid, dominant arm). The test articles were pre-
pared and administered by unblinded staff who took no further
part in the study. Vaccine and placebo injections were admin-
istered in overwrapped syringes to obscure contents to other
study staff and participants. Participants attended study sites
for screening (days –21 to 0) and on days0 (dose 1), 21 (dose 2),
42, and 182. Telephone interviews were conducted on day 84.
A site visit or telephone interview was conducted on day 364.
Immunogenicity Assessments
Immunogenicity outcome measures were hemagglutination
inhibition (HAI) titers and microneutralizing (MN) antibody
titers. The coprimary immunogenicity objectives were (1) to
evaluate vaccine-homologous HAI responses in both age strata
for fulﬁllment of US Food and Drug Administration Center for
Biologic Evaluation and Research (CBER) licensure criteria for
the acceleratedapprovalofpandemic inﬂuenzavaccines [7],and
(2) to test the equivalence of vaccine-homologous HAI geo-
metric mean titers (GMTs) of 3 consecutive vaccine lots in
participants aged 18–49 years at day 42. Secondary endpoints
included HAI responses at day 182 and in participants aged 18–
60 and R61 years (European Union Committee for Medicinal
Products for Human Use [CHMP] age strata [8]) and in par-
ticipants aged R75 years, and day 42 MN antibody responses
against A/Indonesia/05/2005 and clade 1 A/Vietnam/1194/2004.
HAI responses were measured using an established assay
method modiﬁed for horse rather than avian erythrocytes [9–
12], and MN assays were performed according to previously
described methods [9, 11]. All serum samples were tested in
duplicate by blinded personnel. The 50% neutralization titers
were calculated using the Reed and Muench method [13].
The HAI endpoints were seroconversion rate, deﬁned as the
percentage of participants who had pre- and postvaccination
titers of ,1:10 and R1:40, respectively, or showed a signiﬁcant
increase in antibody titer (a prevaccination titer of R1:10 and
R4-fold increase in postvaccination titer); and seroprotection
1730 d JID 2011:203 (15 June) d Langley et alrate, deﬁned as the percentage of participants with titers of
R1:40. All values were calculated with 95% conﬁdence intervals
(CIs). CBER licensure criteria require the lower limits of the
95% CIs for seroconversion rate to be R40% and R30% for
participants aged 18–64 and R65 years, respectively, and for
seroprotection rate to be R70% and R60% for participants
aged 18–64 and R65 years, respectively.
For the analysis of CHMP criteria, point estimates of the sero-
conversion rate needed to be .40% and .30% for participants
aged 18–60 and R61 years, respectively, and the seroprotection
rate needed to be .70% and .60% for subjects aged 18–60 and
R61 years, respectively [8]. The geometric mean fold rise
(GMFR) was deﬁned as the geometric mean of the within-subject
ratios of pre- and postvaccination reciprocal HAI titers. GMFRs of
.2.5 and .2 . 0w e r er e q u i r e di nt h e1 8 – 6 0a n dR61-year-old age
groups, respectively, to fulﬁll the CHMP licensure criterion [8].
For the 3 H5N1 vaccine lots, group GMT ratios were calcu-
lated using an analysis of covariance model; vaccine lots were
considered equivalent if the 2-sided 95% CIs for all of the GMT
ratios were between 0.67 and 1.5.
MN assays were performed on a subgroup of subjects selected
at randomization and exploratory analyses presented descrip-
tively. Participants with an antibody titer of ,1:28 were con-
sidered seronegative. The MN vaccine response rate was deﬁned
as the percentage of participants achieving R4-fold increase
in titer relative to the prevaccination titer. MN GMTs were
described, and 95% CIs presented for all values.
Safety Assessments
The coprimary safety objectives were to describe solicited and
unsolicited adverse events (AEs). Solicited local and general
symptoms were recorded by participants using diary cards for
7 days after each dose and graded using a standard scale [5].
Solicited local events were presumed to be vaccine related;
investigators provided causality assessments for solicited general
events. Assessments of lymph node enlargement and tenderness
were conducted using standard grading deﬁnitions at baseline
and days 21 and 42. In addition, the following were assessed
prospectively: all reports of spontaneously offered AEs (termed
unsolicited AEs) from day 0 to day 84, and serious AEs, medically
attended events, and adverse events of special interest/potentially
immune-mediated disorders (AESIs/pIMDs) from day 0 to day
364 (visit window day 349 to day 379). All AEs were coded by
preferred term and primary system organ class [14]. A protocol
amendment (8 July 2008) required participants to give additional
informed written consent at the day 364 safety assessment.
On 20 October 2008, in response to a request from CBER, the
list of AESI/pIMDs included in the analysis plan was extended.
Analyses
The target sample size was 4400 subjects, 3300 receiving H5N1
vaccine and 1100 receiving placebo. Sample size calculations
to support the primary hypothesis tests indicated that there
would be 90% power to meet the coprimary objectives if a total
of 1569 participants aged 18–64 years, 399 participants aged
R65 years, and 399 participants aged 18–49 years in each vac-
cinelothad evaluableresults,anda subsetofsubjects preselected
at randomization were tested by HAI to provide these numbers
(assuming %5% attrition).
The primary safety analyses were performed on the total
vaccinated cohort, including subjects who received R1d o s eo f
vaccine or placebo for whom any postvaccination data were
available. The immunogenicity analysis was performed on the
according-to-protocol immunogenicity cohort, including sub-
jects with complete data for the primary immunogenicity end-
points and not fulﬁlling any elimination criterion. The lot-to-lot
vaccine equivalence analysis was performed on participants
aged 18–49 years in the according-to-protocol immunogenicity
cohort who received H5N1 vaccine. The descriptive MN anti-
body analysis was performed on a randomly selected subset of
H5N1 vaccine recipients.
Solicited AEs were tabulated per subject, including severity
scoresanddurationofsymptoms.UnsolicitedAEswerecodedby
preferred term and primary system organ class using the Medical
Dictionary for Regulatory Activities [14]. Descriptive summaries
included participants with any solicited event, with grade 2 and
grade 3 events, and with unsolicited AEs, with 95% CIs.
RESULTS
Participants
Of 4561 participants randomized, all received H5N1 vaccine or
placebo (Figure 1). There were 3072 participants in the 18–
64-year-old stratum and 1489 in the R65-year-old stratum.
A sufﬁcient number of particiants were enrolled to provide
a safety database of R3000 H5N1 vaccine recipients. Baseline
characteristics were balanced in the vaccine and placebo groups
(Table 1). Vaccination began 28 January 2008, and the last
participant completed the day 42 visit on 22 April 2008. The last
day 364 safety assessment was performed on 25 November 2009.
Immunogenicity
HAI assay. The CBER and CHMP targets for vaccine-
homologous HAI responses were exceeded in all age strata at
day 42 in H5N1 vaccine recipients (Figure 2). Day 42 serocon-
version rates and seroprotection rates with H5N1 vaccine were
both 90.8% (95% CI, 89.3%–92.2%) in the 18–64-year-old
stratum and were 74.0% (95% CI, 69.4%–78.2%) and 74.5%
(95% CI, 69.9%–78.7%), respectively, in the R65-year-old
stratum. Similar responses were seen in the CHMP age strata.
GMFRs at day 42 fulﬁlled targets in the 18–60 and R61 years
strata (Table 2). Immune responses persisted at day 182 in
H5N1 vaccine recipients. Seroconversion rates and seropro-
tection rates in the placebo groups were low, at 0%–8.3%.
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revealed at day 42. The adjusted GMTs for lots 1, 2, and 3 were
275.8, 291.7, and 333.5, respectively. The adjusted GMT ratio
was 0.95 (95% CI, 0.78–1.15) for lots 1 and 2; 0.83 (95% CI,
0.68–1.00) for lots 1 and 3; and 0.87 (95% CI, 0.72–1.06) for
lots 2 and 3.
MN antibody assay. Before vaccination, 72% (n 5 136) and
28.3% (n 5 13) of participants aged 18–64 and R65 years,
respectively, were seronegative for vaccine-homologous MN
antibodies,and59.7%(n5108)and18.2%(n58),respectively,
were seronegative for MN antibodies to clade 1 A/Vietnam/1194/
2004. In the H5N1 vaccine groups, MN antibodies developed
at day 42 against the vaccine-homologous virus and the clade
1 A/Vietnam strain (Figure 3). At day 182, total MN vaccine
response rates against the vaccine-homologous strain in the 18–
64 years and R65 years strata were 85.6% (95% CI, 79.7%–
90.4%) and 51.1% (95% CI, 35.8%–66.3%), respectively.
Exploratory analyses showed a strong and highly signiﬁcant
positive linear correlation between log-transformed vaccine-
homologous MN and HAI responses at day 42 and day 182 in
both the 18–64 and R65 years strata and a weaker but still
signiﬁcant correlation between A/Indonesia/5/2005 HAI re-
sponses and cross-reactive MN antibody responses to A/Viet-
nam/1194/2004 (data not shown).
Reactogenicity and Safety
Solicited adverse events. The frequency of solicited local and
general AEs during the 7-day postvaccination periods is seen
Figure 1. Study flow diagram.
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groupsandwas reportedby2024(89.3%)of 2267H5N1vaccine
recipients aged 18–64 years, compared with 171 (22.2%) of
754 in the placebo group, and by 784 (70.7%) of 1109 H5N1
vaccine recipientsagedR65years,comparedwith53(14.4%) of
368 in the placebo group. Pain was reported to be grade 1 or 2
in the majority of participants; grade 3 pain in the H5N1vaccine
groups was reported by 141 (6.2%) of 2267 in the 18–64 years
stratum, compared with 6/754 (0.8%) in the placebo group;
and by 15 (1.4%) of 1109 in the R65 years stratum, compared
with 2 (0.5%) of 368 in the placebo group. Pain lasted a mean
of 2.8 days in the H5N1 vaccine group and 1.9 days in the
placebo group (the standard deviation for pain duration in
H5N1 group is 1.34, and is 1.21 in the Placebo group).
Muscleachewasthemostcommonsolicitedgeneraleventand
was reported by 1526 (45.2%) of 3375 H5N1 vaccine recipients
and 231 (20.6%) of 1123 placebo recipients. Grade 3 general
events occurred in 0.8%–3.2% of H5N1 vaccine recipients and
0.9%–2.4% of placebo recipients. Oral temperatures of R39C
were reported by ,1% of participants in each group.
The incidence of AEs after the ﬁrst and second doses was
87.4%and80.3%,respectively,forH5N1vaccineand46.0%and
32.6%, respectively, for placebo in the 18–64 years stratum, and
69.0% and 65.9%, respectively, for H5N1 vaccine, and 32.3%
and 22.9%, respectively, for placebo in the R65 years stratum.
Unsolicited adverse events. From day 0 to day 84, R1
unsolicited AEs were reported by 1017 (44.1%) of 2304
participants aged 18–64 years in the H5N1 vaccine group and
321 (41.8%) of 768 participants aged 18–64 years in the placebo
group and by 467 (41.8%) of 1118 participants aged R65
years in the H5N1 vaccine group and 130 (35.0%) of 371 par-
ticipants aged R65 years in the placebo group (Table 3).
Transient, and generally mild, axillary discomfort was reported
by 0.3% of H5N1 vaccine recipients and no placebo recipients,
but physician-observed lymphadenopathy was uncommon.
AEs by system organ class showed a numerically higher
incidence of ‘‘gastrointestinal disorders’’ among H5N1 vaccine
recipients than among placebo recipients, although 95% CIs
overlapped for each individual AE term: nausea, 2.9% and 2.1%;
diarrhea, 2.7% and 2.2%; and vomiting, 1.1% and 0.9%, re-
spectively.FourparticipantsintheH5N1vaccinegroupreported
injectionsitereactions(painn52,pruritusn52)thatoccurred
beyond the 7-day postvaccination period, and 1 of these par-
ticipants reported injection site pain occurring more than 14
days after vaccination. The incidence of grade 3 unsolicited AEs
was 6.9% (236/3422) among H5N1 vaccine recipients and 6.8%
(78/1139) among placebo recipients.
Serious AEs, medically attended events, and AESI/pIMDs.
Serious AEs, medically attended events, and AESI/pIMDs were
assessed from day 0 to the day 364 visit window in the total
vaccinated cohort. One or more serious AEs were reported by
111 (3.2%) of 3422 vaccine recipients and 45 (4.0%) of 1139
placebo recipients, and there was no differential temporal clus-
tering among vaccine recipients, compared with placebo
Table 1. Patient Demographics and Characteristics in the Total Vaccinated Cohort
Characteristic
Aged 18–64 years Aged R65 years
Vaccine (n 5 2304) Placebo (n 5 768) Vaccine (n 5 1118) Placebo (n 5 371)
Age, mean years (range) 38.5 (18–64) 38.7 (18–64) 71.9 (65–91) 72.1 (65–89)
Age stratum, no. (%)
18–49 years 1707 (74.1) 568 (74.0) ..
50–64 years 597 (25.9) 200 (26.0) ..
65–74 years .. 783 (70.0) 261 (70.4)
R75 years .. 335 (30.0) 110 (29.6)
Female sex, no. (%) 1328 (57.6) 424 (55.2) 621 (55.5) 196 (52.8)
Race, n (%)
White; European heritage 1980 (85.9) 647 (84.2) 1050 (93.3) 345 (93)
African heritage/African American 219 (9.5) 90 (11.7) 40 (3.6) 14 (3.8)
White; Arabic/North African heritage 30 (1.3) 8 (1.0) 19 (1.7) 7 (1.9)
American Indian or Alaskan native 10 (0.4) 7 (0.9) 1 (0.1) 0
Asian
Central/South 7 (0.3) 0 1 (0.1) 1 (0.3)
East 6 (0.3) 1 (0.1) 2 (0.2) 2 (0.5)
Japanese 2 (0.1) 1 (0.1) 0 0
Southeast 9 (0.4) 6 (0.8) 2 (0.2) 1 (0.3)
Native Hawaiian/other Paciﬁc Islander 5 (0.2) 2 (0.3) 0 0
Weight, mean kg (SD) 82.6 (21.15) 81.8 (20.64) 80.9 (17.51) 80.8 (17.97)
NOTE. The candidate vaccine was H5N1 A/Indonesia/05/2005 (IBCDC-RG2) adjuvanted with AS03A (tocopherol-based oil-in-water emulsion). SD, standard
deviation.
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by 1027 (30%) of 3422 vaccine recipients and 346 (30.4%) of
1139 in the placebo group. No medically attended events were
reported by .2.1% of subjects for any preferred term in either
group.
There were 4 deaths (0.1%) in the vaccine group (myocardial
infarction, ovarian carcinoma with metastases to the liver,
malignant neoplasm, and diabetes mellitus/liver disease) and 7
deaths (0.6%) in the placebo group (malignant brain neoplasm,
cardiomegaly, cardiac disorder prior to motor vehicle accident,
gunshot, malignant neoplasm of the tongue, pneumonia, and
a report of death without a speciﬁed diagnosis in an 89-year-old
woman) during the follow-up period. Three deaths (1 vaccinee
and 2 placebo recipients) occurred within 3 weeks of vaccine
exposure.
Twelve participants (0.4%) in the vaccine group and 1 par-
ticipant (0.1%) in the placebo group reported AESIs/pIMDs.
Eight subjects were aged 18–64 years, and 5 were .64 years.
In the H5N1 vaccine group, 2 subjects reported psoriasis and 2
reported polymyalgia rheumatica, and there was 1 report each
of celiac disease, Crohn’s disease, autoimmune hepatitis, rheu-
matoid arthritis, facial palsy, erythema nodosum, radiculitis,
and fourth cranial nerve palsy. One subject with polymyalgia
rheumatica also was diagnosed with temporal arteritis. These
events were not temporally clustered, and none were assessed as
vaccine related by the investigators.
DISCUSSION
In this large, multicenter, phase III study, a 2-dose schedule
of 3.75 lgH AA S 0 3 A-adjuvanted H5N1 A/Indonesia/05/2005
inﬂuenza vaccine induced vaccine-homologous HAI antibody
titers that fulﬁlled licensure criteria for seroconversion and
seroprotection in adults aged 18–64 and R65 years (US licen-
sure age strata) [7], and in adults aged 18–60 and R61 years
(European licensure age strata) [8], at 42 days after the primary
dose. The majority of participants in all age strata retained
A/Indonesia/05/2005 HAI titers of R1:40 at 6 months. In
addition, the immunogenic consistency of 3 consecutive lots of
antigen, combined with 3 consecutive lots of adjuvant, was re-
vealed by adjusted GMT ratios at day 42. These observations
validate the selection of an AS03A-adjuvanted formulation
previously based on phase I/II data [3].
In addition to developing antigen-sparing pandemic vaccines,
it has been suggested that national pandemic and prepandemic
planning incorporate vaccination strategies whereby a popu-
lation is primed with stockpiled avian inﬂuenza vaccine, then
subsequently vaccinated with a pandemic vaccine matched to
the emergent inﬂuenza strain [15–17]. Such a strategy would
require vaccines that induce cross-reactivity against drift vari-
ant viruses, since inﬂuenza viruses can evolve into phylogene-
tically and antigenically distinct clades, and stockpiled vaccine
might not exactly match the eventual pandemic strain [1].
Figure 2. Hemagglutination inhibition assay responses against the vaccine-homologous strain in the according-to-protocol immunogenicity cohort (day
42) and the day 182 immunogenicity cohort. The candidate vaccine was H5N1 A/Indonesia/05/2005 (IBCDC-RG2) adjuvanted with AS03A (tocopherol-
based oil-in-water emulsion).
1734 d JID 2011:203 (15 June) d Langley et alProtective cross-reactive responses have been demonstrated
in preclinical studies in which ferrets that received AS03-
adjuvanted A/Vietnam/1194/2004 vaccine subsequently sur-
vived a lethal vaccine-heterologous challenge with A/Indonesia/
05/2005 [18], and clinical studies have shown that a 2-dose
series of AS03A-adjuvanted A/Vietnam/1194/2004 vaccine
elicits cross-reactive immune responses against clade 2 strains
when doses are given 21 days apart, and 6 or 12 months apart
[4, 19–22]. This study provides additional evidence of cross-
reactive MN immune responses against clade 1 A/Vietnam/
1194/2004 following administration of AS03A-adjuvanted A/
Indonesia/05/2005 vaccine.
Noneofthe 18–64-year-oldgroupand0.3%ofthe R65-year-
old group had HAI antibody titers of .1:10 against the vaccine
strain at baseline. However, .70% of participants aged R65
years were seropositive for MN antibodies against the vaccine-
homologous and/or drift-variant strain before vaccination,
including 11 of 12 participants aged R75 years who were
seropositive for A/Vietnam/1194/2004. This phenomenon has
been observed in previous studies, and it is thought that elderly
people with prolonged natural exposure to seasonal inﬂuenza
viruses and/or multiple lifetime vaccinations may develop
antibodies with antigenic cross-reactivity with H5N1 strains
[23, 24].
Previous exposure to seasonal inﬂuenza vaccination has been
reported to reduce immune responses to subsequent pandemic
inﬂuenza vaccination [25–29]. Recent experience with AS03A-
adjuvanted H1N1 pandemic inﬂuenza vaccine showed that
although licensure criteria for immunogenicity against the
vaccine strain were consistently fulﬁlled, postvaccination anti-
body titers were lower in subjects who had recently received
trivalent seasonal inﬂuenza vaccination, compared with those
who had not [30]. The inﬂuence of preexisting antibody levels,
previous inﬂuenza vaccination, or intercurrent seasonal
inﬂuenza on immune responses to pandemic inﬂuenza vaccine
was beyond the scope of this study. The substantial immune
responses in both age strata suggest that preexisting cross-
reactive antibody does not have a dominating impact on im-
munogenicity to AS03A-adjuvanted H5N1 vaccine that would
impede its general use to address an advancing pandemic. While
we cannot evaluate the possibility that intercurrent seasonal
inﬂuenza might have negatively inﬂuenced immune responses
in some subjects, the virtual absence of antibody increases in the
concurrent placebo group suggests that intercurrent seasonal
inﬂuenza infections did not inﬂate our estimates of vaccine
immunogenicity. Moreover, although elderly people are noted
to have reduced seroconversion to inﬂuenza vaccines, all
immunogenicity criteria were met for older persons in this
study, albeit with lower GMTs than achieved in younger adults.
The acceptability of vaccine programs, even in the absence
of severe or substantial AEs, must be considered in the
Table 2. Hemagglutination Inhibition (HAI) Assay: Geometric Mean Titers (GMT) and Geometric Mean Fold Rise (GMFR) in the
According-to-Protocol Immunogenicity Cohort (Day 42) and the Day 182 Immunogenicity Set
HAI GMT n (95% CI) HAI GMFR n (95% CI)
Age
Treatment
group Prevaccination
a Day 42 Day 182 Day 42 Day 182
18–64 years Vaccine 1571 5.0 (5.0–5.0) 1571 249.0 (231.8–267.5) 366 36.2 (31.0–42.2) 1571 49.6 (46.2–53.3) 366 7.2 (6.2–8.4)
Placebo 76 5.0 (5.0–5.0) 76 5.1 (4.9–5.4) 37 5.5 (4.8–6.5) 76 1.0 (1.0–1.1) 37 1.1 (1.0–1.3)
R65 years Vaccine 396 5.2 (5.1–5.3) 396 81.9 (69.7–96.2) 91 44.8 (33.3–60.4) 396 15.8 (13.4–18.5) 91 8.8 (6.5–11.9)
Placebo 40 5.0–(5.0–5.0) 40 5.5 (4.5–6.8) 19 5.4 (4.6–6.3) 40 1.1 (0.9–1.4) 19 1.1 (0.9–1.3)
18–60 years Vaccine 1488 5.0 (5.0–5.0) 1488 258.0 (239.7–277.7) 353 37.5 (31.8–43.6) 1488 51.4 (47.8–55.3) 353 7.4 (6.3–8.7)
Placebo 68 5.0 (5.0–5.0) 68 5.2 (4.9–5.5) 29 5.7 (4.7–6.9) 68 1.0 (1.0–1.1) 29 1.1 (0.9–1.4)
R61 years Vaccine 479 5.2 (5.0–5.3) 479 89.0 (77.1–102.7) 104 39.6 (29.9–52.5) 479 17.2 (14.9–19.9) 104 7.8 (5.9–10.4)
Placebo 48 5.0 (5.0–5.0) 48 5.5 (4.6–6.5) 27 5.3 (4.7–5.8) 48 1.1 (0.9–1.3) 27 1.1 (0.9–1.2)
R75 years Vaccine 119 5.1 (5.0–5.2) 119 75.2 (55.7–101.5) 22 45.4 (25.2–81.8) 119 14.8 (11.0–20.0) 22 9.1 (5.0–16.4)
Placebo 12 5.0 (5.0–5.0) 12 7.1 (3.3–15.2) 4 5.0 (5.0–5.0) 12 1.4 (0.7–3.0) 4 1.0 (1.0–1.0)
NOTE. GMFR is deﬁned as the mean of the within-subject ratios of pre- and postvaccination reciprocal HAI titers; to fulﬁll the European licensure criterion,
GMFR .2.5 (18–60 years of age) and .2.0 (R61 years of age); there was no US criterion for GMFR. CI, conﬁdence interval.
a According-to-protocol immunogenicity cohort.
Figure 3. Neutralizing antibody geometric mean titers against vaccine-
homologous and vaccine-heterologous strains in the neutralizing antibody
set. The candidate vaccine was H5N1 A/Indonesia/05/2005 (IBCDC-RG2)
adjuvanted with AS03A (tocopherol-based oil-in-water emulsion).
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pain, muscle aches, headache, and fatigue were higher among
H5N1 vaccine recipients than among placebo recipients, al-
though about 20% of placebo recipients also reported these AEs.
The duration of these transient reactions was typically 2–3 days,
and grade 3 reactions were uncommon; adherence to second
doses was R95%. Rates of all unsolicited AEs, objectively as-
sessed enlargement of the axillary and/or supraclavicular nodes,
and symptomatic lymphadenopathy did not differ meaningfully
between treatment groups. Nine participants discontinued
participation because ofanAE, andthese werebalancedbetween
the H5N1 vaccine and placebo groups. Serious AEs were
uncommon, occurring in 4% and 3.2% of placebo and H5N1
vaccine recipients, respectively. Thirty percent of participants
in each group experienced at least 1 medically attended event.
TwelveH5N1vaccine recipients and1 placebo recipient had1
of a heterogenous group of AESI/pIMDs, with 1 subject in the
H5N1 vaccine group reporting both polymyalgia rheumatica
and temporal arteritis. The disease process predated receipt
of the vaccine or had a potential alternative etiology in at least
one-third of participants. The overall rate of AESI/pIMDs was
,0.3%, and this clinical trial did not have sufﬁcient power to
evaluate any potential association of these rare events with the
vaccine. Although these events will be closely monitored in
Table 3. Most Frequent (R1% in a Treatment Group) Spontaneously Reported (Unsolicited) Adverse Events From Day 0 to Day 84 in the
Total Vaccinated Cohort
18–64 Years of age R65 Years of age
Adverse event
Vaccine
(n 5 2304) no.
(%; 95% CI)
Placebo
(n 5 768) no.
(%; 95% CI)
Vaccine
(n 5 1118) no.
(%; 95% CI)
Placebo
(n 5 371) no.
(%; 95% CI)
R1 unsolicited symptom 1017 (44.1; 42.1–46.2) 321 (41.8; 38.3–45.4) 467 (41.8; 38.9–44.7) 130 (35.0; 30.2–40.1)
Nasopharyngitis 116 (5.0; 4.2–6.0) 29 (3.8; 2.5–5.4) 40 (3.6; 2.6–4.8) 11 (3.0; 1.5–5.2)
Oropharyngeal pain 91 (3.9; 3.2–4.8) 39 (5.1; 3.6–6.9) 34 (3.0; 2.1–4.2) 12 (3.2; 1.7–5.6)
Headache 73 (3.2; 2.5–4.0) 31 (4.0; 2.8–5.7) 28 (2.5; 1.7–3.6) 8 (2.2; 0.9–4.2)
Nausea 78 (3.4; 2.7–4.2) 20 (2.6; 1.6–4.0) 20 (1.8; 1.1–2.7) 4 (1.1; 0.3–2.7)
Upper respiratory tract infection 73 (3.2; 2.5–4.0) 25 (3.3; 2.1–4.8) 27 (2.4; 1.6–3.5) 13 (3.5; 1.9–5.9)
Cough 66 (2.9; 2.2–3.6) 28 (3.6; 2.4–5.2) 29 (2.6; 1.7–3.7) 6 (1.6; 0.6–3.5)
Nasal congestion 59 (2.6; 2.0–3.3) 20 (2.6; 1.6–4.0) 11 (1.0; 0.5–1.8) 2 (0.5; 0.1–1.9)
Diarrhoea 57 (2.5; 1.9–3.2) 14 (1.8; 1.0–3.0) 34 (3.0; 2.1–4.2) 11 (3.0; 1.5–5.2)
Back pain 43 (1.9; 1.4–2.5) 19 (2.5; 1.5–3.8) 21 (1.9; 1.2–2.9) 3 (0.8; 0.2–2.3)
Sinusitis 56 (2.4; 1.8–3.1) 13 (1.7; 0.9–2.9) 17 (1.5; 0.9–2.4) 5 (1.3; 0.4–3.1)
Injection site pruritus 56 (2.4; 1.8–3.1) 13 (1.7; 0.9–2.9) 23 (2.1; 1.3–3.1) 1 (0.3; 0–1.5)
Pain in extremity 25 (1.1; 0.7–1.6) 6 (0.8; 0.3–1.7) 19 (1.7; 1.0–2.6) 4 (1.1; 0.3–2.7)
Lymphadenopathy 22 (1.0; 0.6–1.4) 14 (1.8; 1.0–3.0) 3 (0.3; 0.1–0.8) 1 (0.3; 0–1.5)
Rhinorrhoea 28 (1.2; 0.8–1.8) 14 (1.8; 1.0–3.0) 12 (1.2; 0.6–2.0) 3 (0.8; 0.2–2.3)
Inﬂuenza like illness 38 (1.6; 1.2–2.3) 12 (1.6; 0.8–2.7) 8 (0.7; 0.3–1.4) 8 (2.2; 0.9–4.2)
Bronchitis 31 (1.3; 0.9–1.9) 8 (1.0; 0.5–2.0) 12 (1.3; 0.7–2.1) 7 (1.9; 0.8–3.8)
Musculoskeletal pain 12 (0.5; 0.3–0.9) 5 (0.7; 0.2–1.5) 15 (1.3; 0.8–2.2) 5 (1.3; 0.4–3.1)
NOTE. The candidate vaccine was H5N1 A/Indonesia/05/2005 (IBCDC-RG2) adjuvanted with AS03A (tocopherol-based oil-in-water emulsion). CI, conﬁdence
interval.
Figure 4. Solicited adverse events during the 7-day postvaccination period (doses 1 and 2 pooled) in the total vaccinated cohort.
1736 d JID 2011:203 (15 June) d Langley et alfuture trials, large postmarketing surveillance databases would
likely be needed to detect such associations given the low
background incidence of these diagnoses, their heterogeneous
pathophysiology, and the need to account for factors such as
age, sex, and temporal and geographical clustering [31].
In summary, a 2-dose schedule of AS03A-adjuvanted 3.75 lg
A/Indonesia/05/2005 HA elicited immune responses that ful-
ﬁlled licensure criteria in adults and elderly adults, including
participants aged R75 years. The vaccine was associated with a
higher rate of transient injection site reactions and systemic
symptoms than was placebo.
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